Cresco Labs Analyst Ratings
Cresco Labs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/24/2023 | 700.56% | Cantor Fitzgerald | → $14.25 | Maintains | Overweight |
| 12/30/2022 | 700.56% | Cantor Fitzgerald | $15 → $14.25 | Maintains | Overweight |
| 12/20/2022 | 40.45% | Cowen & Co. | $7 → $2.5 | Downgrades | Outperform → Market Perform |
| 12/02/2022 | 152.81% | Wedbush | → $4.5 | Initiates Coverage On | → Outperform |
| 08/18/2022 | 237.08% | Piper Sandler | $9 → $6 | Maintains | Overweight |
| 08/18/2022 | 742.7% | Cantor Fitzgerald | $19 → $15 | Maintains | Overweight |
| 03/24/2022 | 405.62% | Piper Sandler | $14 → $9 | Maintains | Overweight |
| 11/15/2021 | 967.42% | Cantor Fitzgerald | $12 → $19 | Maintains | Overweight |
| 11/03/2021 | 574.16% | Cantor Fitzgerald | $12.65 → $12 | Maintains | Overweight |
| 08/05/2021 | 658.43% | Cantor Fitzgerald | $21.5 → $13.5 | Maintains | Overweight |
| 07/07/2021 | 1922.47% | Jefferies | → $36 | Initiates Coverage On | → Buy |
| 01/20/2021 | 1079.78% | Cantor Fitzgerald | $18 → $21 | Maintains | Overweight |
| 11/19/2020 | 911.24% | Cantor Fitzgerald | $16 → $18 | Maintains | Overweight |
| 10/30/2020 | 798.88% | Cantor Fitzgerald | $15 → $16 | Maintains | Overweight |
| 08/21/2020 | 742.7% | Cantor Fitzgerald | $11 → $15 | Maintains | Overweight |
| 06/12/2020 | 135.96% | Needham | → $4.2 | Initiates Coverage On | → Hold |
| 05/29/2020 | 517.98% | Cantor Fitzgerald | $9.5 → $11 | Maintains | Overweight |
| 05/27/2020 | 433.71% | Cantor Fitzgerald | $8 → $9.5 | Maintains | Overweight |
| 04/28/2020 | 349.44% | Cantor Fitzgerald | $10 → $8 | Maintains | Overweight |
| 03/30/2020 | 461.8% | Cantor Fitzgerald | $12 → $10 | Maintains | Overweight |
| 02/14/2020 | 574.16% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 09/13/2019 | 686.52% | Cowen & Co. | → $14 | Initiates Coverage On | → Outperform |
| 08/13/2019 | 517.98% | Piper Sandler | → $11 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/24/2023 | 700.56% | 康託·菲茨傑拉德 | → $14.25 | 維護 | 超重 |
| 12/30/2022 | 700.56% | 康託·菲茨傑拉德 | $15 → $14.25 | 維護 | 超重 |
| 12/20/2022 | 40.45% | 考恩公司 | $7 → $2.5 | 評級下調 | 跑贏→市場表現 |
| 12/02/2022 | 152.81% | 韋德布什 | → $4.5 | 開始承保 | →跑贏大盤 |
| 08/18/2022 | 237.08% | 派珀·桑德勒 | $9 → $6 | 維護 | 超重 |
| 08/18/2022 | 742.7% | 康託·菲茨傑拉德 | $19 → $15 | 維護 | 超重 |
| 03/24/2022 | 405.62% | 派珀·桑德勒 | $14 → $9 | 維護 | 超重 |
| 11/15/2021 | 967.42% | 康託·菲茨傑拉德 | $12 → $19 | 維護 | 超重 |
| 11/03/2021 | 574.16% | 康託·菲茨傑拉德 | $12.65 → $12 | 維護 | 超重 |
| 08/05/2021 | 658.43% | 康託·菲茨傑拉德 | $21.5 → $13.5 | 維護 | 超重 |
| 07/07/2021 | 1922.47% | 傑富瑞 | → $36 | 開始承保 | →購買 |
| 01/20/2021 | 1079.78% | 康託·菲茨傑拉德 | $18 → $21 | 維護 | 超重 |
| 11/19/2020 | 911.24% | 康託·菲茨傑拉德 | $16 → $18 | 維護 | 超重 |
| 10/30/2020 | 798.88% | 康託·菲茨傑拉德 | $15 → $16 | 維護 | 超重 |
| 08/21/2020 | 742.7% | 康託·菲茨傑拉德 | $11 → $15 | 維護 | 超重 |
| 06/12/2020 | 135.96% | 李約瑟 | → $4.2 | 開始承保 | →保留 |
| 05/29/2020 | 517.98% | 康託·菲茨傑拉德 | $9.5 → $11 | 維護 | 超重 |
| 05/27/2020 | 433.71% | 康託·菲茨傑拉德 | $8 → $9.5 | 維護 | 超重 |
| 04/28/2020 | 349.44% | 康託·菲茨傑拉德 | $10 → $8 | 維護 | 超重 |
| 03/30/2020 | 461.8% | 康託·菲茨傑拉德 | $12 → $10 | 維護 | 超重 |
| 02/14/2020 | 574.16% | 康託·菲茨傑拉德 | → $12 | 開始承保 | →超重 |
| 09/13/2019 | 686.52% | 考恩公司 | → $14 | 開始承保 | →跑贏大盤 |
| 08/13/2019 | 517.98% | 派珀·桑德勒 | → $11 | 開始承保 | →超重 |
What is the target price for Cresco Labs (CRLBF)?
Cresco Labs(CRLBF)的目標價是多少？
The latest price target for Cresco Labs (OTCQX: CRLBF) was reported by Cantor Fitzgerald on February 24, 2023. The analyst firm set a price target for $14.25 expecting CRLBF to rise to within 12 months (a possible 700.56% upside). 7 analyst firms have reported ratings in the last year.
Cresco Labs(OTCQX：CRLBF)的最新目標價是由Cantor Fitzgerald於2023年2月24日報道的。這家分析公司將目標價定為14.25美元，預計CRLBF將在12個月內升至(可能上漲700.56%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Cresco Labs (CRLBF)?
Cresco Labs(CRLBF)的最新分析師評級是多少？
The latest analyst rating for Cresco Labs (OTCQX: CRLBF) was provided by Cantor Fitzgerald, and Cresco Labs maintained their overweight rating.
Cresco Labs(OTCQX：CRLBF)的最新分析師評級由Cantor Fitzgerald提供，Cresco Labs維持其增持評級。
When is the next analyst rating going to be posted or updated for Cresco Labs (CRLBF)?
Cresco Labs(CRLBF)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cresco Labs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cresco Labs was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
分析師在進行了廣泛的研究後得出了股票評級，這些研究包括查看公開的財務報表，與Cresco Labs的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Cresco Labs的上一次評級是在2023年2月24日提交的，所以你應該預計下一次評級將在2024年2月24日左右的某個時候公佈。
Is the Analyst Rating Cresco Labs (CRLBF) correct?
分析師對Cresco Labs(CRLBF)的評級正確嗎？
While ratings are subjective and will change, the latest Cresco Labs (CRLBF) rating was a maintained with a price target of $0.00 to $14.25. The current price Cresco Labs (CRLBF) is trading at is $1.78, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但Cresco Labs(CRLBF)的最新評級保持不變，目標價在0.00美元至14.25美元之間。Cresco Labs(CRLBF)目前的交易價格為1.78美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。